Cargando…

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

We evaluated the association of mutations in 34 candidate genes and response to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic mutations identified by next-generation sequencing. Most patients (93%) had ≥1 mutation (mean=2.6/patient). The overall response rate to az...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cedena, M. Teresa, Rapado, Inmaculada, Santos-Lozano, Alejandro, Ayala, Rosa, Onecha, Esther, Abaigar, María, Such, Esperanza, Ramos, Fernando, Cervera, José, Díez-Campelo, María, Sanz, Guillermo, Rivas, Jesús Hernández, Lucía, Alejandro, Martínez-López, Joaquin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739787/ https://www.ncbi.nlm.nih.gov/pubmed/29291002 http://dx.doi.org/10.18632/oncotarget.22157

Ejemplares similares

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2018)

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
por: Palomo, Laura, et al.
Publicado: (2019)

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
por: Martín, Iván, et al.
Publicado: (2017)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
por: Toribio-Castelló, Sofía, et al.
Publicado: (2023)

P714: DISSECTING THE CLINICAL HETEROGENEITY OF ISOLATED TRISOMY 8 MYELODYSPLASTIC SYNDROMES THROUGH MUTATIONAL PROFILE
por: María Toribio Castelló, Sofía, et al.
Publicado: (2023)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
por: Varghese, Leila N., et al.
Publicado: (2021)

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
por: Falconi, Giulia, et al.
Publicado: (2018)

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
por: Ramos, Fernando, et al.
Publicado: (2016)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
por: Martín-Izquierdo, Marta, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012)

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
por: Valencia, A, et al.
Publicado: (2014)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
por: Hashimoto, Miki, et al.
Publicado: (2019)

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes
por: Yang, Yanli, et al.
Publicado: (2020)

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes
por: Abáigar, María, et al.
Publicado: (2016)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
por: Ibáñez, Mariam, et al.
Publicado: (2020)

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
por: Onecha, Esther, et al.
Publicado: (2020)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain
por: Crespo, Carlos, et al.
Publicado: (2013)

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
por: Daitoku, Shinya, et al.
Publicado: (2018)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
por: Ayala, Rosa, et al.
Publicado: (2021)

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
por: Ramos, Pedro Marques, et al.
Publicado: (2023)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_34kfdj21q46no0dgh8qd5apbcs